Cancer Immunotherapy of Wilms Tumor: a Narrative Review

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Sep 5

PMID 39235074

Authors

Yu Lin He

Jin Yan Liu

Rahma Taher Almgrami

Ying Zhong Fan

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Wilms tumor (WT) is the most common malignant tumor of the urinary system in children. Though the traditional treatment of surgery plus radiotherapy and chemotherapy achieves exciting clinical efficacy, in relapsed and refractory cases, the long-term overall survival rates are poor. Besides, chemotherapy and radiation have serious long-term toxic side effects on children. Cancer immunotherapy is a new tumor therapy that works by activating the body's immune system to allow immune cells to kill tumor cells more efficiently. Currently, cancer immunotherapy has been tested in clinical trials or basic studies in WT. This article reviews the current status of clinical trials and basic research of cancer immunotherapy in WT to promote the application of cancer immunotherapy in WT patients.

Citing Articles

A Retrospective Review of 28 Cases of Pediatric Malignant Renal Tumors at a Single Institution.

Kawano T, Sugita K, Masuya R, Nishida N, Nagano A, Murakami M Diseases. 2025; 13(2).

PMID: 39997047 PMC: 11854009. DOI: 10.3390/diseases13020040.

References

Leruste A, Beccaria K, Doz F . CAR-T cells for pediatric brain tumors: Present and future. Bull Cancer. 2021; 108(10S):S109-S116. DOI: 10.1016/j.bulcan.2021.06.002. View

Baxevanis C, Perez S, Papamichail M . Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009; 46(4):167-89. DOI: 10.1080/10408360902937809. View

Stokes C, Stokes W, Kalapurakal J, Paulino A, Cost N, Cost C . Timing of Radiation Therapy in Pediatric Wilms Tumor: A Report From the National Cancer Database. Int J Radiat Oncol Biol Phys. 2018; 101(2):453-461. DOI: 10.1016/j.ijrobp.2018.01.110. View

Hong B, Dong R . Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review. Transl Cancer Res. 2022; 10(3):1559-1567. PMC: 8799117. DOI: 10.21037/tcr-20-3302. View

Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View

Cafri G, Gartner J, Zaks T, Hopson K, Levin N, Paria B . mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020; 130(11):5976-5988. PMC: 7598064. DOI: 10.1172/JCI134915. View

Sun L, Guo H, Jiang R, Lu L, Liu T, He X . Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumour Biol. 2015; 37(1):799-806. DOI: 10.1007/s13277-015-3845-9. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K . WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer. 2010; 55(2):352-5. DOI: 10.1002/pbc.22522. View

10.

Li W, Guo L, Rathi P, Marinova E, Gao X, Wu M . Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2016; 28(5):437-448. PMC: 5444493. DOI: 10.1089/hum.2016.025. View

11.

Wagner L, Adams V . Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther. 2017; 10:2097-2106. PMC: 5396947. DOI: 10.2147/OTT.S124008. View

12.

Behfar M, Muhammadnejad S, Abdolahi S, Mohseni R, Shoae-Hassani A, Monzavi S . Adoptive NK-cell transfer as a potential treatment paradigm for Wilms tumor: A preclinical study. Pediatr Blood Cancer. 2022; 69(8):e29676. DOI: 10.1002/pbc.29676. View

13.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

14.

Hu F, Huang D, Luo Y, Zhou P, Lv C, Wang K . Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells. J Immunother Cancer. 2020; 8(2). PMC: 7368548. DOI: 10.1136/jitc-2019-000498. View

15.

Narayan V, Barber-Rotenberg J, Jung I, Lacey S, Rech A, Davis M . PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022; 28(4):724-734. PMC: 10308799. DOI: 10.1038/s41591-022-01726-1. View

16.

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View

17.

Lei Q, Wang D, Sun K, Wang L, Zhang Y . Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Front Cell Dev Biol. 2020; 8:672. PMC: 7385189. DOI: 10.3389/fcell.2020.00672. View

18.

Chen E, Jonker D, Loree J, Kennecke H, Berry S, Couture F . Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 2020; 6(6):831-838. PMC: 7206536. DOI: 10.1001/jamaoncol.2020.0910. View

19.

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

20.

Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanojevic M . Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Adv. 2021; 6(2):473-485. PMC: 8791594. DOI: 10.1182/bloodadvances.2021005343. View